文献速递血栓与止血

艾曲泊帕联合双醋瑞因对比艾曲泊帕单药治疗原发免疫性血小板减少症患者:一项多中心、随机、开放标签2期试验

Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial.
PubMed 文献 · Blood · 2024-01-01

本研究纳入全剂量艾曲泊帕治疗14天无应答的原发免疫性血小板减少症患者,1:1随机接受艾曲泊帕联合双醋瑞因(n=50)或艾曲泊帕单药(n=52)治疗。第15天联合组总缓解率为44%,单药组为13%(P=0.0009);第28天联合组为42%,单药组为12%(P=0.0006);联合组缓解持续时间更长(P=0.0004)。联合治疗耐受良好。

要点

  • 全剂量艾曲泊帕治疗14天无应答的ITP患者,加用双醋瑞因可提高总缓解率。
  • 第15天总缓解率联合组44% vs 单药组13%(P=0.0009),第28天42% vs 12%(P=0.0006)。
  • 联合组缓解持续时间长于单药组(P=0.0004),常见不良事件为呼吸道感染和胃肠道反应。

核心结论

  • 艾曲泊帕联合双醋瑞因耐受良好,较艾曲泊帕单药诱导更高的总缓解率和更长的缓解持续时间,为全剂量艾曲泊帕治疗14天无应答的ITP患者提供一种补救治疗选择。

研究设计与样本

  • 多中心、随机、开放标签2期试验,纳入全剂量艾曲泊帕治疗14天无应答的原发免疫性血小板减少症患者,1:1随机分为艾曲泊帕联合双醋瑞因组(n=50)和艾曲泊帕单药组(n=52)。
  • 研究注册于ClinicalTrials.gov,注册号NCT04917679。

主要发现

  • 第15天总缓解率联合组为44%,单药组为13%(P=0.0009)。
  • 第28天总缓解率联合组为42%,单药组为12%(P=0.0006)。
  • 联合组缓解持续时间长于单药组(P=0.0004)。
  • 联合组最常见的两种治疗中出现的不良事件为呼吸道感染和胃肠道反应,单药组为乏力和呼吸道感染。

关键数值与推荐

  • 总缓解定义为血小板计数≥30×10^9/L、血小板计数较基线至少翻倍且无出血。

临床怎么用

  • 作者认为,对于全剂量艾曲泊帕治疗14天无应答的ITP患者,艾曲泊帕联合双醋瑞因可作为补救治疗选择。
  • 作者指出,本研究有望改善接受血小板生成素受体激动剂治疗患者的照护,减少快速转换至其他较不优选疗法的需要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to compare the efficacy and safety of eltrombopag plus diacerein vs eltrombopag alone in patients with primary immune thrombocytopenia (ITP) who were previously unresponsive to 14 days of eltrombopag treatment at the full dose. Recruited patients were randomly assigned 1:1 to receive either eltrombopag plus diacerein (n = 50) or eltrombopag monotherapy (n = 52). Overall response rate, defined as a platelet count of ≥30 × 109/L, at least doubling of the baseline platelet count, and no bleeding, was reached in 44% of patients in the eltrombopag plus diacerein group compared with 13% in the eltrombopag group at day 15 (P = .0009), and reached in 42% of patients in the combination group compared with 12% in the monotherapy group at day 28 (P = .0006). The addition of diacerein to eltrombopag also led to a longer duration of response (P = .0004). The 2 most common treatment-emergent adverse events were respiratory infection and gastrointestinal reactions in the combination group, and fatigue and respiratory infection in the eltrombopag group. In conclusion, eltrombopag plus diacerein was well tolerated, and induced higher overall response rates and longer duration of response than eltrombopag alone, offering a rejuvenating salvage therapy for patients with ITP unresponsive to 14 days of full dosage eltrombopag. Our work has the potential to enhance the care of patients treated with thrombopoietin receptor agonists, reducing the need for rapid transitions to less-preferable therapies. This study is registered at ClinicalTrials.gov as #NCT04917679.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sun L, Huang X, Wang J, et al. Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial. Blood. 2024. PMID: 38958479. doi:10.1182/blood.2024025067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。